ME02692B - NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA - Google Patents
NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCAInfo
- Publication number
- ME02692B ME02692B MEP-2017-87A MEP8717A ME02692B ME 02692 B ME02692 B ME 02692B ME P8717 A MEP8717 A ME P8717A ME 02692 B ME02692 B ME 02692B
- Authority
- ME
- Montenegro
- Prior art keywords
- peptide
- seq
- nucleic acid
- sfnplwlrl
- sfnplwlrf
- Prior art date
Links
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 title claims 2
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims 2
- 230000002496 gastric effect Effects 0.000 title claims 2
- 238000009169 immunotherapy Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
Claims (15)
1. Peptid koji ima celokupnu dužinu od između lO i 14 aminokiselina koji sadrži sekvencu izabranu iz grupea) sekvenca koja sadrži ID BR. SEKV 2 i b) varijanta ID BR. SEKV 2 koja indukuje unakrsnu reakciju T ćelija sa navedenim peptidom, naznačeno time što je navedena varijanta izabrana iz grupe sekvenci SFNPLWLRI, SFNPLWLRL, SFNPLWLRF, SFNPLWLRL i SFNPLWLRF za upotrebu u medicini.
2.Peptid za upotrebu u skladu sa patentnim zahtevom l, koji ima sposobnost da se vezuje za molekul humanog glavnog kompleksa gena tkivne podudarnosti (MHC) klase I.
3.Peptid za upotrebu u skladu sa patentnim zahtevom l ili 2, naznačeno time što peptid sadrži nepeptidne veze.
4.Fuzioni protein koji obuhvata peptidnu sekvencu kao deo izabran iz grupe a) sekvence koja se sastoji od ID BR. SEKV 2 i b) varijante ID BR. SEKV 2 izabrane iz grupe sekvenci SFNPLWLRI, SFNPLWLRL, SFNPLWLRF, SFNPLWLRL i SFNPLWLRF, koje konkretno sadrže N-terminalne aminokiseline HLA-DR antigen-asociranog nepromenljivog lanca (Ii).
5.Nukleinska kiselina, koja kodira peptid za upotrebu u skladu sa bilo kojim od patentnih zahteva od l do 4, pod uslovom da peptid nije kompletan humani protein, naznačeno time što je navedena nukleinska kiselina poželjno DNK, cDNK, PNK, RNK ili njihova kombinacija, ili vektor ekspresije koji eksprimira navedenu nukelinsku kiselinu.
6.Nukleinska kiselina ili vektor ekspresije u skladu sa patentnim zahtevom 5 za upotrebu u medicini.
7.Ćelija domaćin, koja sadrži nukleinsku kiselinu ili vektor ekspresije u skladu sa patentnim zahtevom 5, koja je antigen-prezentujuća ćelija. • - 134-
8.Metod za proizvodnju peptida za upotrebu u skladu sa bilo kojim od patentnih zahteva od l do 4, pri čemu metod obuhvata kultiviranje ćelije domaćina u skladu sa patentnim zahtevom 7, kao i izolaciju peptida iz ćelije domaćina ili medijuma za njeno kultiviranje.
9.In vitro metod za proizvodnju aktiviranih citotoksičnih T limfocita (CTL), metod koji se sastoji od dovođenja u kontakt in vitro CTL sa humanim MHC molekulima klase I sa ubačenim antigenom eksprimiranim na površini prikladne antigen-prezentujuće ćelije u toku vremenskog perioda koji je dovoljan da se navedeni CTL aktiviraju na antigen specifičan način, naznačeno time što je navedeni antigen peptid u skladu sa patentnim zahtevom l ili 2.
10. Metod u skladu sa patentnim zahtevom 9, naznačeno time što navedena antigen prezentujuća ćelija sadrži vektor ekspresije koji eksprimira navedeni peptid u skladu sa patentnim zahtevom l ili 2.
11. Aktivirani citotoksični T limfocit (CTL), proizveden metodom u skladu sa patentnim zahtevom 9 ili 10, koji selektivno prepoznaje peptid u skladu sa patentnim zahtevom l ili
12.Citotoksični T limfocit (CTL) u skladu sa patentnim zahtevom ll za upotrebu u lečenju malignog tumora, koji ubija ciljne ćelije kod pacijenta, naznačeno time što navedene ciljne ćelije aberantno prezentuju peptid u skladu sa ID BR. SEKV 2.
13.Peptid u skladu sa patentnim zahtevom l ili 2, nukleinska kiselina ili vektor ekspresije u skladu sa patentnim zahtevom 5, ćelija u skladu sa patentnim zahtevom 7, ili aktivirani citotoksični T limfocit u skladu sa patentnim zahtevom 12 za primenu u lečenju raka, kao što su, na primer, karcinom želuca, gastrointestinalni, kolorektalni, karcinom pankreasa, pluća ili bubrega.
14.Peptid, nukleinska kiselina ili vektor ekspresije, ćelija ili aktivirani citotoksični T limfocit za upotrebu u skladu sa patentnim zahtevom 13, naznačeno time što je navedeni Jek vakcina.
15. Neterapijska upotreba peptida koji ima celokupnu dužinu od između 10 14 aminokiselina, koje obuhvataju sekvencu izabranu iz grupe a) sekvence koja sadrži ID BR. SEKV 2 i b) varijante ID BR. SEKV 2 izabrane iz grupe sekvenci SFNPLWLRI, SFNPLWLRL, ' SFNPLWLRF, SFNPLWLRL i SFNPLWLRF za stvaranje i razvoj antitela koja su specifična protiv kompleksa MHC/peptid koji sadrži navedeni peptid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31570410P | 2010-03-19 | 2010-03-19 | |
| GBGB1004551.6A GB201004551D0 (en) | 2010-03-19 | 2010-03-19 | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP14184348.2A EP2845604B1 (en) | 2010-03-19 | 2011-03-15 | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02692B true ME02692B (me) | 2017-10-20 |
Family
ID=42227949
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-287A ME03569B (me) | 2010-03-19 | 2011-03-15 | Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni karcinom i karcinom želuca |
| MEP-2017-87A ME02692B (me) | 2010-03-19 | 2011-03-15 | NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA |
| MEP-2015-122A ME02229B (me) | 2010-03-19 | 2011-03-15 | NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-287A ME03569B (me) | 2010-03-19 | 2011-03-15 | Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni karcinom i karcinom želuca |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-122A ME02229B (me) | 2010-03-19 | 2011-03-15 | NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA |
Country Status (30)
| Country | Link |
|---|---|
| US (25) | US10064913B2 (me) |
| EP (9) | EP3363456B1 (me) |
| JP (10) | JP5891181B2 (me) |
| KR (13) | KR102388761B1 (me) |
| CN (8) | CN108456242A (me) |
| AU (1) | AU2011229199B2 (me) |
| BR (1) | BR112012023692B1 (me) |
| CA (5) | CA3206214A1 (me) |
| CY (5) | CY1119366T1 (me) |
| DK (6) | DK3195873T3 (me) |
| EA (8) | EA202091242A3 (me) |
| ES (8) | ES2544529T3 (me) |
| GB (1) | GB201004551D0 (me) |
| HK (1) | HK1226297A1 (me) |
| HR (6) | HRP20150867T1 (me) |
| HU (6) | HUE051478T2 (me) |
| LT (5) | LT2923708T (me) |
| ME (3) | ME03569B (me) |
| MX (7) | MX2012010813A (me) |
| MY (2) | MY178651A (me) |
| NZ (7) | NZ769435A (me) |
| PH (4) | PH12012501821A1 (me) |
| PL (6) | PL2547354T3 (me) |
| PT (6) | PT2547354E (me) |
| RS (6) | RS54182B1 (me) |
| SG (4) | SG183880A1 (me) |
| SI (6) | SI3363456T1 (me) |
| TW (9) | TWI715332B (me) |
| UA (3) | UA126787C2 (me) |
| WO (1) | WO2011113819A2 (me) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7604662B2 (en) | 2007-07-13 | 2009-10-20 | Boston Scientific Scimed, Inc. | Endoprostheses containing boride intermetallic phases |
| DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP2400035A1 (en) * | 2010-06-28 | 2011-12-28 | Technische Universität München | Methods and compositions for diagnosing gastrointestinal stromal tumors |
| US9040046B2 (en) | 2011-01-31 | 2015-05-26 | Kai Xu | Sodium pump antibody agonists and methods of treating heart disease using the same |
| SG10201608552WA (en) * | 2011-10-28 | 2016-12-29 | Oncotherapy Science Inc | Topk Peptides And Vaccines Including The Same |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| ES2887580T3 (es) * | 2012-03-19 | 2021-12-23 | Stemline Therapeutics Inc | Métodos para el tratamiento y seguimiento del estado del cáncer |
| SI3536334T1 (sl) | 2012-05-16 | 2021-11-30 | Stemline Therapeutics Inc. | Cepiva proti raku, ki ciljajo na rakave matične celice |
| JP6255593B2 (ja) | 2012-07-10 | 2018-01-10 | オンコセラピー・サイエンス株式会社 | Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン |
| US20150285802A1 (en) * | 2012-07-18 | 2015-10-08 | Dana-Farber Cancer Institute, Inc. | Methods for treating, preventing and predicting risk of developing breast cancer |
| JP6212249B2 (ja) * | 2012-08-08 | 2017-10-11 | 学校法人 京都産業大学 | カルシウムポンプ制御物質のスクリーニング方法、並びに、メラニン色素合成阻害物質のスクリーニング方法 |
| GB2521562B (en) | 2012-08-30 | 2020-07-08 | Univ Leland Stanford Junior | Anti-tumor T cell immunity induced by high dose radiation |
| HRP20192262T1 (hr) | 2013-08-05 | 2020-03-06 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc) |
| TWI775117B (zh) * | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| EP2876442A1 (en) * | 2013-11-22 | 2015-05-27 | Institut de Cancérologie de l'Ouest | Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US10532088B2 (en) | 2014-02-27 | 2020-01-14 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
| US10813984B2 (en) | 2014-04-24 | 2020-10-27 | Rhode Island Hospital | Aspartate-β-hydroxylase induces epitope-specific T cell responses in tumors |
| US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
| GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| KR101644599B1 (ko) | 2014-10-14 | 2016-08-16 | 연세대학교 산학협력단 | 미토콘드리아 단백질 uqcrb 관련 질환 유전자발현 세포 구축 및 이를 활용한 uqcrb 기능조절 활성평가계 구축 |
| MA40737A (fr) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| IL284985B2 (en) | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| KR20240151873A (ko) | 2015-03-17 | 2024-10-18 | 이매틱스 바이오테크놀로지스 게엠베하 | 췌장암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합 |
| GB201504502D0 (en) * | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| CA2982452A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物 |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| JP6838004B2 (ja) | 2015-06-11 | 2021-03-03 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物 |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| JP2018518956A (ja) * | 2015-06-19 | 2018-07-19 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 免疫療法で使用するための新規ペプチドおよびペプチド組み合わせおよび膵臓がんおよびその他のがんに対して使用するためにスキャフォールドを作製する方法 |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| IL308735A (en) | 2015-07-01 | 2024-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201512369D0 (en) * | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| PH12018501893A1 (en) | 2015-08-28 | 2022-05-02 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| US20170136108A1 (en) * | 2015-08-28 | 2017-05-18 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| KR102601499B1 (ko) * | 2015-11-06 | 2023-11-13 | 연세대학교 산학협력단 | miRNA 발현 수준으로부터 UQCRB 관련 질병을 진단하는 방법 |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| US20170199961A1 (en) | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| IL302705A (en) | 2016-03-01 | 2023-07-01 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides, and cell-based medicaments for use in immunotherapy against urinary bladder cancer and other cancers |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) * | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| GB201604458D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| EA201892333A1 (ru) * | 2016-04-21 | 2019-03-29 | Имматикс Байотекнолоджиз Гмбх | Иммунотерапия меланомы и других видов рака |
| CR20200608A (es) | 2016-04-21 | 2021-01-20 | Immatics Biotechnologies Gmbh | INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551) |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| HUE057094T2 (hu) * | 2016-08-17 | 2022-04-28 | Immatics Biotechnologies Gmbh | T-sejt receptorok és a velük végzett immunterápia |
| ZA201900664B (en) | 2016-08-17 | 2021-09-29 | Paul Ehrlich Strasse 15 Tuebingen 72076 Germany | T cell receptors and immune therapy using the same |
| DE102016115246C5 (de) | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| CN109923121B (zh) | 2016-11-22 | 2022-12-23 | 武汉华大吉诺因生物科技有限公司 | 多肽及其应用 |
| WO2018098715A1 (zh) * | 2016-11-30 | 2018-06-07 | 深圳华大基因研究院 | 多肽及其应用 |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| TW201841934A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於治療癌症免疫治療的新穎肽及其肽組合物 |
| EP3725327A3 (en) * | 2017-04-10 | 2021-01-20 | Immatics Biotechnologies GmbH | Peptides and combination thereof for use in the immunotherapy against cancers |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| LT3652215T (lt) | 2017-07-14 | 2021-05-25 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| CN118888004A (zh) | 2017-10-10 | 2024-11-01 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| DE102017125888A1 (de) * | 2017-11-06 | 2019-05-23 | Immatics Biotechnologies Gmbh | Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie |
| IL274505B2 (en) * | 2017-11-06 | 2024-04-01 | Immatics Biotechnologies Gmbh | Novel engineered t cell receptors and immune therapy using the same |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER |
| EP3765071A4 (en) | 2018-03-12 | 2022-05-25 | The Children's Hospital of Philadelphia | METHODS AND COMPOSITIONS FOR USE OF TUMOR AUTOGENS IN ADOPTIVE IMMUNOTHERAPY |
| MX2020014191A (es) | 2018-06-19 | 2021-03-09 | Dsm Ip Assets Bv | Variantes de enzimas lipoliticas. |
| US20210380661A1 (en) * | 2018-10-16 | 2021-12-09 | Texas Tech University System | Method to Express, Purify, and Biotinylate Eukaryotic Cell-Derived Major Histocompatibility Complexes |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
| ES2991645T3 (es) | 2019-06-06 | 2024-12-04 | Immatics Biotechnologies Gmbh | Clasificación con contraselección mediante péptidos de secuencia similar |
| KR102397922B1 (ko) * | 2020-02-19 | 2022-05-13 | 서울대학교 산학협력단 | 신규한 종양-관련 항원 단백질 olfm4 및 이의 용도 |
| EP4206334A4 (en) | 2020-08-28 | 2025-01-01 | Industry Academic Cooperation Foundation Keimyung University | Micro rna biomarker for predicting drug response to antidiabetics and use thereof |
| WO2022109258A1 (en) * | 2020-11-19 | 2022-05-27 | Board Of Regents, The University Of Texas System | Methods and compositions comprising mhc class i peptides |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| MX2023012899A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Polipeptidos de union a antigeno bma031 mejorados. |
| CN114732898B (zh) * | 2022-04-01 | 2023-05-09 | 中国人民解放军军事科学院军事医学研究院 | 一种CpG佐剂与抗原定点共价结合方法 |
| AU2023262596A1 (en) | 2022-04-28 | 2024-12-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| US20240325448A1 (en) * | 2022-09-29 | 2024-10-03 | Jerome Canady Research Institute for Advanced Biological and Technological Sciences | Cold atmopsheric plasma treated pan-cancer epitope peptide within the collagen type vi a-3 (col6a3) protein as cancer vaccine |
| WO2024077071A2 (en) * | 2022-10-05 | 2024-04-11 | The Johns Hopkins University | Nanoparticles for delivery of immunoregulatory materials to t cells |
| EP4661892A1 (en) * | 2023-02-08 | 2025-12-17 | Navigen, Inc. | Tnf-alpha binding agents and methods of using the same |
| CN116102468B (zh) * | 2023-02-22 | 2024-07-09 | 中国科学技术大学 | 靶向人脂质运载蛋白2的先导化合物或其药学上可接受的盐及其制备方法与应用 |
| WO2024225764A1 (ko) * | 2023-04-26 | 2024-10-31 | 한국과학기술원 | 섬유아세포 활성화 단백질의 면역우세 에피토프 펩타이드 및 이의 용도 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN119679951A (zh) * | 2025-02-11 | 2025-03-25 | 安徽医科大学 | E3泛素连接酶syvn1的抑制物质在制备胃癌治疗药物中的应用 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IE53176B1 (en) | 1978-12-22 | 1988-08-17 | Biogen Nv | Recombinant dna molecules and their method of production |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| WO1994029347A1 (en) | 1993-06-03 | 1994-12-22 | Therapeutic Antibodies Inc. | Antibody fragments in therapy |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| WO1997026328A1 (en) | 1996-01-17 | 1997-07-24 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US8299321B2 (en) | 1998-06-16 | 2012-10-30 | Monsanto Technology Llc | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| CA2343934A1 (en) * | 1998-09-25 | 2000-04-06 | The Children's Medical Center Corporation | Short peptides which selectively modulate the activity of protein kinases |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| JP2003530083A (ja) * | 1999-12-10 | 2003-10-14 | エピミューン インコーポレイテッド | ペプチドおよび核酸組成物を使用する、ＨＥＲ２／ｎｅｕに対する細胞性免疫応答の誘導 |
| JP4310104B2 (ja) | 2002-09-28 | 2009-08-05 | 英俊 猪子 | マイクロサテライト遺伝多型マーカを用いる遺伝子のマッピング方法 |
| US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| US20070067865A1 (en) | 2000-09-05 | 2007-03-22 | Kovalic David K | Annotated plant genes |
| EP1317275A1 (de) * | 2000-09-06 | 2003-06-11 | Müller, Friederike | Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors |
| EP1330543A4 (en) | 2000-10-02 | 2006-03-29 | Bayer Ag | IN CANCER TISSUE, EXPRESSED NUCLEIC ACID SEQUENCES DIFFERENTIATE |
| US6673549B1 (en) * | 2000-10-12 | 2004-01-06 | Incyte Corporation | Genes expressed in C3A liver cell cultures treated with steroids |
| USH2191H1 (en) | 2000-10-24 | 2007-06-05 | Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
| US20040072753A1 (en) * | 2000-11-01 | 2004-04-15 | Milton Nathaniel Gavin Nicolas | Peptides for use in the treatment of alzheimer's disease |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2002078524A2 (en) * | 2001-03-28 | 2002-10-10 | Zycos Inc. | Translational profiling |
| WO2002078516A2 (en) * | 2001-03-30 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| AU2003304464A1 (en) | 2002-03-15 | 2005-03-29 | Monsanto Technology Llc | Nucleic acid molecules associated with oil in plants |
| US20050221350A1 (en) * | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| WO2004014867A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Matrix metalloproteinase inhibitors and methods for identification of lead compounds |
| US20060188889A1 (en) * | 2003-11-04 | 2006-08-24 | Christopher Burgess | Use of differentially expressed nucleic acid sequences as biomarkers for cancer |
| WO2005049806A2 (en) * | 2003-03-14 | 2005-06-02 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| US20070037204A1 (en) * | 2003-08-08 | 2007-02-15 | Hiroyuki ABURANTAI | Gene overexpressed in cancer |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20070054278A1 (en) | 2003-11-18 | 2007-03-08 | Applera Corporation | Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof |
| WO2005072050A2 (en) * | 2004-01-27 | 2005-08-11 | Compugen Usa, Inc. | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer |
| EP1568383A3 (en) | 2004-02-27 | 2005-11-16 | Antisense Pharma GmbH | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment |
| US20070039069A1 (en) | 2004-03-22 | 2007-02-15 | Rogers James A | Nucleic acid molecules associated with oil in plants |
| EP2343384A3 (en) | 2004-03-23 | 2012-01-04 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancer |
| WO2006023598A2 (en) * | 2004-08-19 | 2006-03-02 | University Of Maryland, Baltimore | Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| AT501014A1 (de) * | 2004-08-19 | 2006-05-15 | Kury & Zeillinger Oeg | Verfahren und kit zur diagnose einer krebserkrankung, verfahren zum feststellen des ansprechens eines patienten auf die behandlung einer krebserkrankung, therapeutikum zur prophylaxe oder behandlung einer krebserkrankung |
| WO2007005635A2 (en) * | 2005-07-01 | 2007-01-11 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mitotic spindle protein aspm as a diagnostic marker for neoplasia and uses therefor |
| ES2341802T3 (es) * | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| PL1760089T3 (pl) * | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| GB0521958D0 (en) | 2005-10-27 | 2005-12-07 | Ares Trading Sa | vWFA, collagen and kunitz domain containing protein |
| DE102005052384B4 (de) * | 2005-10-31 | 2009-09-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens |
| US20080058272A1 (en) * | 2006-08-29 | 2008-03-06 | Juergen Becker | Nonamer Peptides for Cancer Treatment |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| UA103882C2 (uk) | 2007-07-27 | 2013-12-10 | Імматікс Біотекнолоджіс Гмбх | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина |
| PL2562184T3 (pl) * | 2007-07-27 | 2016-03-31 | Immatics Biotechnologies Gmbh | Nowe immunogenne epitopy do immunoterapii |
| US7892770B2 (en) * | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| NZ562237A (en) * | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| WO2009075883A2 (en) * | 2007-12-12 | 2009-06-18 | University Of Georgia Research Foundation, Inc. | Glycoprotein cancer biomarker |
| KR101184869B1 (ko) * | 2008-04-24 | 2012-09-20 | 이매틱스 바이오테크놀로지스 게엠베하 | 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형 |
| EP2113253B1 (en) * | 2008-04-30 | 2010-03-31 | Immatics Biotechnologies GmbH | Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines |
| UA104572C2 (ru) * | 2008-04-24 | 2014-02-25 | Имматикс Байотекнолоджиз Гмбх | Новые композиции опухолеассоциированных пептидов, которые связываются с молекулами i или ii класса лейкоцитарного антигена человека (hla) для разработки вакцин |
| US8133686B2 (en) * | 2008-05-15 | 2012-03-13 | Van Andel Research Institute | IL-8 as a biomarker for sunitinib resistance |
| TWI526219B (zh) * | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗 |
| EP2337795A2 (en) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201019331D0 (en) * | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| GB201015765D0 (en) * | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| GB201021289D0 (en) * | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
-
2010
- 2010-03-19 GB GBGB1004551.6A patent/GB201004551D0/en not_active Ceased
-
2011
- 2011-03-15 PL PL11711292T patent/PL2547354T3/pl unknown
- 2011-03-15 WO PCT/EP2011/053863 patent/WO2011113819A2/en not_active Ceased
- 2011-03-15 CN CN201810105798.4A patent/CN108456242A/zh active Pending
- 2011-03-15 RS RS20150530A patent/RS54182B1/sr unknown
- 2011-03-15 PL PL18156634T patent/PL3363456T3/pl unknown
- 2011-03-15 EP EP18156634.0A patent/EP3363456B1/en active Active
- 2011-03-15 RS RS20170980A patent/RS56612B1/sr unknown
- 2011-03-15 EP EP17203096.7A patent/EP3329933B1/en active Active
- 2011-03-15 JP JP2012557522A patent/JP5891181B2/ja not_active Expired - Fee Related
- 2011-03-15 US US13/635,896 patent/US10064913B2/en active Active
- 2011-03-15 KR KR1020207026527A patent/KR102388761B1/ko active Active
- 2011-03-15 KR KR1020227004088A patent/KR20220025133A/ko not_active Ceased
- 2011-03-15 LT LTEP15154344.4T patent/LT2923708T/lt unknown
- 2011-03-15 SI SI201131927T patent/SI3363456T1/sl unknown
- 2011-03-15 ES ES11711292.0T patent/ES2544529T3/es active Active
- 2011-03-15 EP EP16156192.3A patent/EP3058947A3/en not_active Withdrawn
- 2011-03-15 PH PH1/2012/501821A patent/PH12012501821A1/en unknown
- 2011-03-15 KR KR1020207026525A patent/KR102324498B1/ko not_active Expired - Fee Related
- 2011-03-15 CN CN202011080378.9A patent/CN112409453A/zh active Pending
- 2011-03-15 EA EA202091242A patent/EA202091242A3/ru unknown
- 2011-03-15 HU HUE18156634A patent/HUE051478T2/hu unknown
- 2011-03-15 LT LTEP14184348.2T patent/LT2845604T/lt unknown
- 2011-03-15 CN CN202011079575.9A patent/CN112409452A/zh active Pending
- 2011-03-15 KR KR1020237031847A patent/KR20230141886A/ko active Pending
- 2011-03-15 RS RS20201304A patent/RS60993B1/sr unknown
- 2011-03-15 EP EP17157398.3A patent/EP3195873B1/en active Active
- 2011-03-15 EA EA201690511A patent/EA039357B1/ru unknown
- 2011-03-15 HU HUE11711292A patent/HUE027036T2/en unknown
- 2011-03-15 UA UAA201801266A patent/UA126787C2/uk unknown
- 2011-03-15 HU HUE15154344A patent/HUE033682T2/en unknown
- 2011-03-15 CN CN201510354965.5A patent/CN105001339B/zh active Active
- 2011-03-15 KR KR1020207026532A patent/KR102324499B1/ko active Active
- 2011-03-15 UA UAA201209114A patent/UA111711C2/uk unknown
- 2011-03-15 MX MX2012010813A patent/MX2012010813A/es active IP Right Grant
- 2011-03-15 DK DK17157398.3T patent/DK3195873T3/da active
- 2011-03-15 CA CA3206214A patent/CA3206214A1/en active Pending
- 2011-03-15 MY MYPI2012700609A patent/MY178651A/en unknown
- 2011-03-15 SI SI201131293T patent/SI2923708T1/sl unknown
- 2011-03-15 BR BR112012023692A patent/BR112012023692B1/pt active IP Right Grant
- 2011-03-15 CN CN202011079539.2A patent/CN112409451B/zh active Active
- 2011-03-15 ES ES15154344.4T patent/ES2642562T3/es active Active
- 2011-03-15 KR KR1020207026530A patent/KR102324500B1/ko active Active
- 2011-03-15 NZ NZ769435A patent/NZ769435A/en not_active IP Right Cessation
- 2011-03-15 EP EP14184348.2A patent/EP2845604B1/en active Active
- 2011-03-15 NZ NZ72784111A patent/NZ727841A/en not_active IP Right Cessation
- 2011-03-15 RS RS20170553A patent/RS56070B1/sr unknown
- 2011-03-15 DK DK11711292.0T patent/DK2547354T3/da active
- 2011-03-15 LT LT17157398T patent/LT3195873T/lt unknown
- 2011-03-15 CA CA2789857A patent/CA2789857C/en active Active
- 2011-03-15 DK DK14184348.2T patent/DK2845604T3/da active
- 2011-03-15 PL PL17157398T patent/PL3195873T3/pl unknown
- 2011-03-15 EA EA201201306A patent/EA024497B1/ru unknown
- 2011-03-15 EA EA202091241A patent/EA202091241A3/ru unknown
- 2011-03-15 EA EA202091233A patent/EA202091233A3/ru unknown
- 2011-03-15 KR KR1020217004318A patent/KR102329791B1/ko active Active
- 2011-03-15 KR KR1020187002782A patent/KR20180014848A/ko not_active Ceased
- 2011-03-15 PT PT117112920T patent/PT2547354E/pt unknown
- 2011-03-15 AU AU2011229199A patent/AU2011229199B2/en not_active Ceased
- 2011-03-15 LT LTEP18156634.0T patent/LT3363456T/lt unknown
- 2011-03-15 ME MEP-2019-287A patent/ME03569B/me unknown
- 2011-03-15 HU HUE17203096A patent/HUE050376T2/hu unknown
- 2011-03-15 ES ES18156634T patent/ES2829375T3/es active Active
- 2011-03-15 HU HUE14184348A patent/HUE032402T2/en unknown
- 2011-03-15 SG SG2012065173A patent/SG183880A1/en unknown
- 2011-03-15 KR KR1020217004319A patent/KR102361467B1/ko not_active Expired - Fee Related
- 2011-03-15 SG SG10201606771SA patent/SG10201606771SA/en unknown
- 2011-03-15 SI SI201131913T patent/SI3329933T1/sl unknown
- 2011-03-15 SG SG10201502093QA patent/SG10201502093QA/en unknown
- 2011-03-15 RS RS20201054A patent/RS60765B1/sr unknown
- 2011-03-15 EP EP11711292.0A patent/EP2547354B1/en active Active
- 2011-03-15 HU HUE17157398A patent/HUE045757T2/hu unknown
- 2011-03-15 RS RS20191340A patent/RS59554B1/sr unknown
- 2011-03-15 NZ NZ708205A patent/NZ708205A/en not_active IP Right Cessation
- 2011-03-15 KR KR1020127027196A patent/KR101656913B1/ko active Active
- 2011-03-15 ES ES20179386T patent/ES2993310T3/es active Active
- 2011-03-15 DK DK18156634.0T patent/DK3363456T3/da active
- 2011-03-15 KR KR1020197005246A patent/KR20190033577A/ko not_active Ceased
- 2011-03-15 UA UAA201512437A patent/UA122047C2/uk unknown
- 2011-03-15 PT PT171573983T patent/PT3195873T/pt unknown
- 2011-03-15 CN CN201180014644.0A patent/CN102905721B/zh active Active
- 2011-03-15 PL PL17203096T patent/PL3329933T3/pl unknown
- 2011-03-15 CA CA3076642A patent/CA3076642C/en active Active
- 2011-03-15 PL PL14184348T patent/PL2845604T3/pl unknown
- 2011-03-15 EA EA202091250A patent/EA202091250A3/ru unknown
- 2011-03-15 KR KR1020167023720A patent/KR101826460B1/ko active Active
- 2011-03-15 NZ NZ711296A patent/NZ711296A/en not_active IP Right Cessation
- 2011-03-15 ES ES14184348.2T patent/ES2626798T3/es active Active
- 2011-03-15 NZ NZ627877A patent/NZ627877A/en not_active IP Right Cessation
- 2011-03-15 HR HRP20150867TT patent/HRP20150867T1/hr unknown
- 2011-03-15 EP EP20179386.6A patent/EP3738606B1/en active Active
- 2011-03-15 SI SI201130546T patent/SI2547354T1/sl unknown
- 2011-03-15 EP EP20179380.9A patent/EP3753570B1/en active Active
- 2011-03-15 LT LTEP17203096.7T patent/LT3329933T/lt unknown
- 2011-03-15 ME MEP-2017-87A patent/ME02692B/me unknown
- 2011-03-15 NZ NZ601438A patent/NZ601438A/en not_active IP Right Cessation
- 2011-03-15 PL PL15154344T patent/PL2923708T3/pl unknown
- 2011-03-15 ES ES17203096T patent/ES2819861T3/es active Active
- 2011-03-15 MX MX2017015735A patent/MX382164B/es unknown
- 2011-03-15 EA EA201792409A patent/EA037019B1/ru unknown
- 2011-03-15 EA EA202091251A patent/EA202091251A3/ru unknown
- 2011-03-15 DK DK17203096.7T patent/DK3329933T3/da active
- 2011-03-15 PT PT151543444T patent/PT2923708T/pt unknown
- 2011-03-15 CN CN202011079527.XA patent/CN112457390A/zh active Pending
- 2011-03-15 NZ NZ769427A patent/NZ769427A/en not_active IP Right Cessation
- 2011-03-15 EP EP15154344.4A patent/EP2923708B1/en active Active
- 2011-03-15 PT PT141843482T patent/PT2845604T/pt unknown
- 2011-03-15 PT PT172030967T patent/PT3329933T/pt unknown
- 2011-03-15 SG SG10201710446PA patent/SG10201710446PA/en unknown
- 2011-03-15 CN CN202011080388.2A patent/CN112430255A/zh active Pending
- 2011-03-15 CA CA2986969A patent/CA2986969C/en active Active
- 2011-03-15 CA CA2936642A patent/CA2936642C/en active Active
- 2011-03-15 DK DK15154344.4T patent/DK2923708T3/en active
- 2011-03-15 PH PH1/2021/551360A patent/PH12021551360A1/en unknown
- 2011-03-15 ME MEP-2015-122A patent/ME02229B/me unknown
- 2011-03-15 ES ES20179380T patent/ES2992110T3/es active Active
- 2011-03-15 PT PT181566340T patent/PT3363456T/pt unknown
- 2011-03-15 KR KR1020207026524A patent/KR102388577B1/ko active Active
- 2011-03-15 ES ES17157398T patent/ES2753206T3/es active Active
- 2011-03-15 SI SI201131182A patent/SI2845604T1/sl unknown
- 2011-03-15 SI SI201131804T patent/SI3195873T1/sl unknown
- 2011-03-18 TW TW108144354A patent/TWI715332B/zh not_active IP Right Cessation
- 2011-03-18 TW TW104113109A patent/TWI621709B/zh active
- 2011-03-18 TW TW109130850A patent/TWI768461B/zh not_active IP Right Cessation
- 2011-03-18 TW TW107110964A patent/TWI681967B/zh not_active IP Right Cessation
- 2011-03-18 TW TW106141450A patent/TWI659967B/zh not_active IP Right Cessation
- 2011-03-18 TW TW109130851A patent/TWI766361B/zh not_active IP Right Cessation
- 2011-03-18 US US13/051,665 patent/US9101585B2/en active Active
- 2011-03-18 TW TW100109429A patent/TWI486445B/zh not_active IP Right Cessation
- 2011-03-18 TW TW111118219A patent/TW202300509A/zh unknown
- 2011-03-18 TW TW109130852A patent/TWI766362B/zh active
-
2012
- 2012-09-06 MY MYPI2016002170A patent/MY197710A/en unknown
- 2012-09-19 MX MX2015001606A patent/MX355074B/es unknown
- 2012-09-19 MX MX2020011673A patent/MX2020011673A/es unknown
- 2012-09-19 MX MX2020011675A patent/MX2020011675A/es unknown
- 2012-09-19 MX MX2020011674A patent/MX2020011674A/es unknown
- 2012-09-19 MX MX2020011672A patent/MX2020011672A/es unknown
-
2013
- 2013-07-10 HK HK16114573.8A patent/HK1226297A1/en unknown
-
2015
- 2015-02-06 US US14/615,539 patent/US9717774B2/en active Active
- 2015-08-25 JP JP2015165375A patent/JP6103608B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-23 PH PH12016500949A patent/PH12016500949B1/en unknown
- 2016-08-05 JP JP2016154278A patent/JP6238258B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-22 JP JP2017030876A patent/JP6535040B2/ja active Active
- 2017-05-04 CY CY20171100486T patent/CY1119366T1/el unknown
- 2017-05-12 HR HRP20170718TT patent/HRP20170718T1/hr unknown
- 2017-06-28 US US15/636,486 patent/US20170304399A1/en not_active Abandoned
- 2017-06-29 US US15/636,958 patent/US9895415B2/en active Active
- 2017-06-30 US US15/639,310 patent/US9993523B2/en active Active
- 2017-06-30 US US15/639,506 patent/US10357540B2/en active Active
- 2017-10-06 HR HRP20171504TT patent/HRP20171504T1/hr unknown
- 2017-10-10 CY CY20171101050T patent/CY1119739T1/el unknown
- 2017-11-22 JP JP2017224260A patent/JP6722644B2/ja active Active
-
2019
- 2019-05-22 US US16/419,818 patent/US10420816B1/en active Active
- 2019-07-03 US US16/502,268 patent/US10478471B2/en active Active
- 2019-09-24 PH PH12019502194A patent/PH12019502194A1/en unknown
- 2019-10-14 HR HRP20191859TT patent/HRP20191859T1/hr unknown
- 2019-10-18 CY CY20191101092T patent/CY1122235T1/el unknown
- 2019-12-13 US US16/714,098 patent/US10905741B2/en not_active Expired - Fee Related
-
2020
- 2020-06-05 US US16/894,186 patent/US10898546B2/en active Active
- 2020-06-05 US US16/894,212 patent/US10933118B2/en active Active
- 2020-06-19 JP JP2020106500A patent/JP7034505B2/ja not_active Expired - Fee Related
- 2020-06-19 JP JP2020106497A patent/JP7107586B2/ja active Active
- 2020-09-14 HR HRP20201467TT patent/HRP20201467T1/hr unknown
- 2020-09-22 CY CY20201100894T patent/CY1123447T1/el unknown
- 2020-11-02 HR HRP20201770TT patent/HRP20201770T1/hr unknown
- 2020-11-04 CY CY20201101040T patent/CY1123762T1/el unknown
-
2021
- 2021-01-28 US US17/161,253 patent/US11077171B2/en active Active
- 2021-02-05 JP JP2021017733A patent/JP7007504B2/ja not_active Expired - Fee Related
- 2021-04-23 US US17/238,943 patent/US11850274B2/en active Active
- 2021-05-14 US US17/320,782 patent/US11883462B2/en active Active
- 2021-05-21 US US17/327,116 patent/US11839643B2/en active Active
- 2021-06-25 US US17/358,676 patent/US11969455B2/en active Active
- 2021-07-23 US US17/383,892 patent/US11975042B2/en active Active
- 2021-07-23 US US17/383,855 patent/US11957730B2/en active Active
- 2021-09-24 US US17/484,568 patent/US20220008506A1/en not_active Abandoned
- 2021-09-24 US US17/484,703 patent/US11273200B2/en active Active
- 2021-10-01 US US17/491,742 patent/US12064465B2/en active Active
- 2021-10-01 US US17/492,219 patent/US11298404B2/en active Active
-
2022
- 2022-04-29 US US17/733,260 patent/US11648292B2/en active Active
- 2022-07-06 JP JP2022108874A patent/JP2022141743A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095464A patent/JP2024116331A/ja active Pending
- 2024-10-18 US US18/920,658 patent/US20250049886A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02692B (me) | NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA | |
| HRP20201228T1 (hr) | Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga | |
| AR121383A2 (es) | Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres | |
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2019515650A5 (me) | ||
| JP2013521789A5 (me) | ||
| HRP20150108T1 (hr) | Peptidna cjepiva za rak koji eksprimira tumoru pridružene antigene | |
| JP2020198875A5 (me) | ||
| JP2010534463A5 (me) | ||
| JP2020182458A5 (me) | ||
| JP2009506762A5 (me) | ||
| HRP20210709T1 (hr) | Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma | |
| HRP20201281T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma | |
| JP2019502360A5 (me) | ||
| HRP20192262T1 (hr) | Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc) | |
| JP2017525336A5 (me) | ||
| JP2018510628A5 (me) | ||
| JP2019536426A5 (me) | ||
| CN112472802B (zh) | 一种细菌外膜囊泡、包含该细菌外膜囊泡的通用纳米疫苗及其制备方法和应用 | |
| HRP20210528T1 (hr) | Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma | |
| JP2020191868A5 (me) | ||
| JP2020191873A5 (me) | ||
| HRP20191671T1 (hr) | Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) | |
| HRP20211753T1 (hr) | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova | |
| CN103360497A (zh) | 一种新型抗肿瘤融合蛋白疫苗及其制备方法和应用 |